Inmunología e inflamación

<p>Satralizumab (SA-237) is a humanized antibody targeting interleukin-6 (IL-6), used in research on neuromyelitis optica spectrum disorder (NMOSD).</p>

<p>GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity and inhibits kinase activity.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human CD248. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human CD248. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human CD248, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human CD248 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

Benzobicyclon is a 4-HPPD) inhibitor and herbicide that is spectrally active against annual grasses, sedges, and broadleaf weeds without toxicity to rice.

<p>MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.</p>

<p>L-NIL inhibits inducible NO synthase (mouse) with an IC50 of 3.3 μM and blocks rat brain NO synthase (IC50: 92 μM).</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human CD248. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human CD248. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human CD248, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human CD248 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>Sirukumab (CNTO-136) is a humanized monoclonal antibody binding to IL-6, inhibiting IL-6-mediated signaling and transcription activator activation.</p>

3'-Sialyllactose sodium is a prebiotic with anti-inflammatory activity that maintains immune homeostasis and can be used to study inflammation.

<p>MIF098 is a MIF antagonist that inhibits the proliferation of pulmonary smooth muscle cells (PASMC) and can be used to study pulmonary hypertension.</p>

Tenivastatin (Simvastatin acid) is an anti-hyperlipidemic HMG-CoA reductase inhibitor used in the study of primary hyperlipidemia.

<p>Propiconazole (PRO) is an orally active brassinosteroid biosynthesis inhibitor and a triazole fungicide with antifungal activity.</p>

Peramivir is a neuraminidase inhibitor used to treat influenza by preventing virus release from cells.

<p>Glimepiride sulfonamide is an antiinflammatory agent.</p>

<p>CBR-470-1 is a glycolytic phosphoglycerate kinase 1 inhibitor and Nrf2 activator that exhibits neuroprotective activity by activating the Keap1-Nrf2 cascade.</p>

<p>PSMA I&amp;T is a PSMA-targeting radioactive compound that can be used as a diagnostic agent for prostate-specific membrane antigen-targeted therapy.</p>

<p>Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit, a selective IL-23p19 antagonist.</p>

Simvastatin acid ammonium (Tenivastatin ammonium) is an HMG-CoA reductase (HMGCR) inhibitor.

<p>L-Kynurenine-d4 is a deuterated isotope compound of L-Kynurenine. L-Kynurenine is a metabolite of tryptophan and an endogenous agonist of the AHR.</p>

<p>PFI-2 is an effective, specific and cell-active lysine methyltransferase SETD7 inhibitor (Ki/IC50: 0.33/2 nM), 1000-fold selectivity over other</p>

<p>Tegoprubart (anti-CD40L mAb) inhibits the CD40-CD40L pathway, reducing immune responses and promoting tolerance in transplant models.</p>

D-Ribose-L-cysteine is the antioxidant glutathione precursor.

<p>Lutikizumab (ABT-981) is a dual-action antibody blocking IL-1α/β, potential osteoarthritis research drug.</p>

<p>Gefurulimab (ALXN-1720) is a bispecific antibody derived from humans, targeting complement C5 and albumin.</p>

<p>Gumokimab (AK 111) is an anti-IL-17A mAb that blocks pro-inflammatory signaling, a candidate for psoriasis and ankylosing spondylitis.</p>

<p>Depemokimab (GSK-3511294) is a long-acting monoclonal antibody targeting IL-15, utilized in asthma research [1] [2].</p>

<p>Ziralimumab（ABX-RB2） is a monoclonal antibody that targets and inhibits IL-2 receptor, thereby modulating the immune response.</p>

<p>Sonelokimab (ALX 0761; M 1095), a trivalent nanobody targeting IL-17A, IL-17F, and serum albumin, may aid in psoriasis research.</p>

<p>Vamikibart is a chimeric, humanized IgG2κ antibody that targets IL6 [1].</p>

<p>Anrukinzumab (IMA-638) is an anti-IL-13 mAb with anti-inflammatory effects, in development for ulcerative colitis and asthma.</p>

<p>Riliprubart (SAR445088) is a humanized monoclonal antibody that acts as an anti-C1s inhibitor in the proximal part of the classical complement system. It selectively targets activated C1s, inhibiting its enzymatic activity on substrates C4 and C2, thereby preventing the formation of the classical pathway C3 convertase, C4b2a [1].</p>

<p>CTX-471, a human monoclonal antibody, targets CD137 with Kd 50-748 nM, for immunomodulation and cancer research.</p>

<p>Grisnilimab (WT1) is a monoclonal antibody targeting CD7. WT1) gene is overexpressed in leukaemia and various types of solid tumours</p>

<p>Tocopherol nicotinate is an antioxidant. It is used for skin conditioning.</p>

<p>Ifinatamab is a humanised monoclonal immunoglobulin,B7-H3 protein.ADC drug Ifinatamab deruxtecan,small cell lung cancer (SCLC).</p>

<p>Lebrikizumab is a humanised monoclonal antibody that targets and inhibits interleukin 13 (IL-13), suppressing Th2 inflammation.asthma and atopic dermatitis.</p>

<p>Keliximab (SB-210396), a chimeric IgG1 anti-CD4 antibody, inhibits T cells and IL-2, for cancer research, K i 1.0 nM.</p>

<p>Tucotuzumab: IgG1 monoclonal antibody targeting EpCAM, fused with IL-2, used as an immunosuppressant and antineoplastic.</p>

<p>Anti-Mouse IL-1b Antibody is an IgG inhibitor specific to mouse IL-1b, derived from an Armenian Hamster host.</p>

<p>Paridiprubart (NI-0101) is a humanised monoclonal antibody targeting TLR4, ameliorative effects in COVID-19 patients with ARDS and rheumatoid arthritis.</p>

<p>Loncastuximab (RB4v1.2) is an anti-CD19 antibody with antitumor effects, used for treating NHL, including DLBCL.</p>

<p>Trabikibart (CSL311) is a human βc-specific antibody inhibiting IL-3, GM-CSF and IL-5, regulating eosinophil survival in chronic inflammatory disease research.</p>

<p>Tebotelimab is a human IgG4κ DART antibody targeting PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM, blocking their interactions and signaling.</p>

<p>BMS-986449 is a CELMoD-type molecular gel that enhances anti-tumor by directing the E3 ubiquitin ligase, Cereblon, to degrade IKZF2 (Helios) and IKZF4 (Eos).</p>

<p>Minretumomab (CC-49) is a mouse monoclonal antibody targeting TAG-72 breast cancer, colon cancer, lung cancer, and pancreatic cancer.</p>

<p>Anti-Mouse TIM-3 Antibody (23C3.N) is an antibody that inhibits mouse TIM-3 (CD366), immune diseases such as experimental autoimmune encephalomyelitis (EAE).</p>

<p>Gevokizumab (S-78989) is a humanised monoclonal antibody targeting IL-1β, allosteric regulation, diabetes, cancer, inflammation, and cardiovascular diseases.</p>

<p>Zanolimumab is a humanised monoclonal antibody targeting CD4, blocking TCR signalling, autoimmune diseases such as rheumatoid arthritisa.</p>

<p>Afasevikumab (RG 7624) is a fully humanised monoclonal antibody that targets and neutralises IL-17A and IL-17F,autoimmune diseases and inflammation.</p>

<p>Anti-Mouse IFN Gamma Antibody is a host Armenian Hamster-derived anti-mouse IFN gamma immunoglobulin G (IgG) inhibitor.</p>

<p>Camoteskimab (AVTX-007) is a human anti-IL-18 antibody for autoinflammatory diseases like AOSD research.</p>

<p>Ocaratuzumab, an Fc-engineered humanized IgG1 anti-CD20 antibody with ~100 pM affinity, enhances ADCC.</p>

<p>Casdozokitug is a human IgG1κ anti-IL-27 antibody that blocks immunosuppressive activity, relevant in tumor immunology and immune checkpoint therapy research.</p>

<p>1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor that suppresses the formation of osteoclasts, functioning by downregulating the signaling pathways of nuclear factor κB ligand receptor activator (Receptor activator of NF-κB ligand, RANKL) and macrophage colony-stimulating factor (M-CSF). This compound is used in the research of metabolic bone diseases.</p>

<p>Lunsekimig (SAR443765) is an IL-13/TSLP bis-antibody that links a nano-antibody targeting IL-13 and a variable region of the heavy chain (VHH) targeting TSLP for use in asthma research.</p>

<p>Encelimab, an anti-LAG3 antibody, prevents LAG-3/MHC II binding, activating T-cells and reducing tumor burden in preclinical lymphoma models.</p>

<p>Crovalimab (SKY59; RO7112689) is an humanised monoclonal antibody that binds to complement C5 , paroxysmal nocturnal haemoglobinuria (PNH).</p>

<p>Puxitatug (INT-016) is a humanised monoclonal antibody targeting VTCN1/B7H4, (ADC) Puxitatug samrotecan, delivering to cancer cells expressing B7-H4.</p>

<p>Sofituzumab is a humanised monoclonal antibody targeting the MUC16 protein,in the synthetic ADC Sofituzumab vedotin, ovarian cancer and pancreatic cancer.</p>

<p>Picankibart (IBI112) is a human recombinant monoclonal antibody targeting IL-23p19, indicated for psoriasis treatment.</p>

<p>Dargistotug (M-6223), a human IgG1 antibody targeting TIGIT, enhances NK and T-cell activity, cytokine secretion, Treg function for immune checkpoint studies.</p>

<p>Inolimomab is a monoclonal antibody targeting CD25 (IL-2R α chain) for studying acute graft-versus-host disease (aGVHD).</p>

<p>Dazukibart (anti-IFNB1 mAb) is a potential treatment for dermatomyositis, an autoimmune disorder with pronounced interferon overexpression.</p>

<p>Photosensitizer-1 (Compound CLB-13) hydrochloride is a photosensitizer [1] .</p>

NSC 31156 is a bioactive chemical.

<p>Faralimomab (64G12) is an immunomodulator, and a murine anti- IFNA1 IgG1 mAb [1] .</p>

<p>Bimekizumab is a humanised monoclonal antibody targeting IL17A/IL17F, blocking inflammation-driven osteoblast differentiation.</p>

<p>Octaethylporphyrin is a stable porphyrin compound used for research.</p>

<p>Duvortuxizumab (MGD 011) is a chimeric, humanized immunoglobulin (IG) antibody that specifically targets CD19 and CD3E receptors [1].</p>

<p>Ebdarokimab (anti-IL-12/23 p40 mAb) inhibits the IL-12/IL-23 pathway and is under clinical investigation for SLE and plaque psoriasis.</p>

<p>Empasiprubart (anti-C2 mAb) inhibits classical &amp; lectin complement pathways upstream of C3, showing efficacy in autoimmune models.</p>

<p>Manfidokimab is an anti-IL-4Rα mAb that blocks IL-4/IL-13 signaling, in trials for atopic dermatitis.</p>

<p>Divozilimab (BCD-132), a humanized monoclonal antibody targeting CD20 (CD20), is utilized in multiple sclerosis research [1].</p>

<p>Gatralimab (anti-CD52 mAb) shows successful lymphocyte depletion &amp; repopulation in Phase 1, supporting its study for relapsing MS.</p>

<p>Imalumab (BAX69), a human IgG1 antibody, targets MIF for ovarian cancer, recurrent ascites, and cancer research.</p>

<p>Photosensitizer-1 (Compound CLB-13) is a photosensitizer [1] .</p>

<p>Fontolizumab (HuZAF) is a humanised IgG1 monoclonal anti-IFN-gamma (IFN-γ) antibody for the study of Crohn's disease.</p>

Anti-IL-12 p70 Antibody (20C2), an IgG1 monoclonal, suppresses interferon-gamma, IL-12-mediated inflammation, paired with a Rat IgG1 kappa control.

<p>Argininosuccinic acid can be obtained during the urea cycle from citrulline, aspartate, and ATP by argininosuccinic acid synthetase.</p>

<p>Lokivetmab: anti-IL31 monoclonal antibody for dog atopic dermatitis research.</p>

<p>Imidazole Salicylate, a non-steroidal anti-inflammatory drug, has limited inhibitory effects on prostaglandin synthesis.</p>

<p>Favezelimab (MK-4280) blocks LAG-3/MHC II interaction, restoring T-cell function, studied in colorectal cancer research and with PD-L1 inhibitors.</p>

<p>Botensilimab (AGEN 1181) is a humanized anti-CTLA-4 antibody activating innate and adaptive immunity, under research for enhancing antitumor responses.</p>

<p>Anti-Mouse CD8α Antibody (2.43) is a mouse-derived IgG2b kappa antibody targeting CD8α in mice,,flow cytometry.</p>

<p>Anti-Mouse IL-6R Antibody (15A7) is an antibody inhibitor targeting mouse IL-6R, derived from rats, widely used in research and experiments</p>

<p>Aspirin DL-lysine: a water-soluble, injectable NSAID that may also hinder cancer growth.</p>

<p>Samalizumab (anti-CD200 mAb) is an immune checkpoint inhibitor under investigation for treating myeloma and B-cell CLL.</p>

<p>Exlinkibart (LVGN-6051) is a humanised monoclonal antibody and agonist targeting CD137/TNFRSF9, inducing cytotoxic T lymphocyte (CTL) proliferation.</p>

<p>Suciraslimab (SM03) is a human IgG1 monoclonal antibody against the B-cell restriction antigen CD22 for rheumatoid arthritis (RA) and B-cell related diseases.</p>

<p>Erzotabart is an IgG1κ antibody targeting CD38, modulating tumor cell metabolism and immune evasion, serving as an investigational oncology research candidate.</p>

<p>Bapotulimab (BAY-1905254) is a human/mouse/monkey cross-reactive monoclonal antibody that targets and inhibits ILDR2, blocking its immunosuppressive activity.</p>

<p>Tirnovetmab (KIND-016) is a fully dog-derived monoclonal antibody targeting IL-31 with high affinity, suitable for investigating canine atopic dermatitis.</p>

<p>Bempikibart (ADX-914) is a fully humanised monoclonal antibody targeting IL-7Rα, inhibiting IL-17 and TSLP (Thymic stromal lymphopoietin), inflammation.</p>

<p>Anti-Mouse IL-1R Antibody is an IgG2b subclass inhibitor targeting the mouse IL-1 receptor, sourced from Armenian hamsters.</p>

<p>Surzebiclimab (BGB-A425), a humanized variant IgG1 monoclonal antibody, targets and binds with high affinity (K D = 0.36 nM) and specificity to the</p>

<p>Anti-Mouse LAG-3 Antibody (C9B7W) is a monoclonal antibody inhibitor targeting the D2 domain of mouse LAG-3 (CD223), thereby enhancing antitumour effects.</p>

<p>Tositumomab is a murine IgG2a lambda antibody targeting CD20 on B cells, used in B cell therapy, immunology studies, and radioimmunoconjugate development.</p>

<p>Lulizumab: Humanized antibody selectively blocking CD28 to prevent T cell activation.</p>

<p>Tifcemalimab (JS004) is a humanized monoclonal antibody targeting BTLA to block HVEM-BTLA interaction and inhibit cancer signaling pathways.</p>

<p>Dresbuxelimab (AK-119), an IgG-κ monoclonal antibody, selectively targets CD73 and is commonly produced using a Chinese Hamster Ovary (CHO) cell expression</p>